-
公开(公告)号:US20050014762A1
公开(公告)日:2005-01-20
申请号:US10489903
申请日:2002-09-17
IPC分类号: A61K31/4409 , A61K31/47 , A61K45/06 , A61P11/00 , A61P11/06 , A61K31/519 , A61K31/4709
CPC分类号: A61K45/06
摘要: The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and leukotriene receptor antagonists for the treatment of respiratory tract disorders.
摘要翻译: 本发明涉及用于治疗呼吸道疾病的PDE4或PDE3 / 4抑制剂和白细胞三烯受体拮抗剂的组合施用。
-
2.Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases 审中-公开
标题翻译: 包含罗氟司特和抗胆碱能药物的协同组合,其选自异丙托铵,羟托吡酮和噻托铵盐,用于治疗呼吸道疾病公开(公告)号:US20060189642A1
公开(公告)日:2006-08-24
申请号:US10550191
申请日:2004-03-26
IPC分类号: A61K31/4745 , A61K31/46 , A61K31/4412
CPC分类号: A61K45/06 , A61K31/439 , A61K2300/00
摘要: The invention relates to the administration of roflumilast oral or intravenously and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.
摘要翻译: 本发明涉及口服或静脉内罗氟司特的给药以及选自异丙托铵,硝基托铵或噻托铵盐的抗胆碱能剂,用于治疗呼吸系统疾病。
-
公开(公告)号:US06489327B1
公开(公告)日:2002-12-03
申请号:US09601317
申请日:2000-10-20
申请人: Thomas Bär , Thomas Martin , Josef Stadlwieser , Wolf-Rüdiger Ulrich , Andreas Dominik , Ulrich Thibaut , Daniela Bundschuh , Rolf Beume , Karl-Josef Goebel , Wolfram Bode , Luis Moroder , Pedro Jose Barbosa Pereira , Andreas Bergner , Robert Huber , Christian Sommerhoff , Norbert Schaschke
发明人: Thomas Bär , Thomas Martin , Josef Stadlwieser , Wolf-Rüdiger Ulrich , Andreas Dominik , Ulrich Thibaut , Daniela Bundschuh , Rolf Beume , Karl-Josef Goebel , Wolfram Bode , Luis Moroder , Pedro Jose Barbosa Pereira , Andreas Bergner , Robert Huber , Christian Sommerhoff , Norbert Schaschke
IPC分类号: A61K31495
CPC分类号: C07D213/81 , C07C279/16 , C07D211/58 , C07D213/82 , C07D295/185 , C07D295/215 , C07D401/14
摘要: The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.
摘要翻译: 本发明涉及用于药物工业用于生产药物的人类类胰蛋白酶的新型抑制剂。
-
4.N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors 审中-公开
标题翻译: N-4-(6-(杂)芳基 - 嘧啶-4-基氨基苯基) - 苯磺酰胺作为激酶抑制剂公开(公告)号:US20080242681A1
公开(公告)日:2008-10-02
申请号:US10586121
申请日:2005-01-19
申请人: Johannes Barsig , Monika Baudler , Daniela Bundschuh , Florian Gantner , Ulrich Graedler , Isabelle Heit , Thomas Martin , Michaela Schaefer , Imre Schlemminger , Josef Stadlwieser , Wolf-Ruediger Ulrich
发明人: Johannes Barsig , Monika Baudler , Daniela Bundschuh , Florian Gantner , Ulrich Graedler , Isabelle Heit , Thomas Martin , Michaela Schaefer , Imre Schlemminger , Josef Stadlwieser , Wolf-Ruediger Ulrich
IPC分类号: A61K31/505 , C07D239/42 , A61P31/00 , A61P35/00 , A61P25/28 , A61P3/10 , A61P9/10 , A61P19/02 , A61P29/00 , A61P17/00 , A61P27/02
CPC分类号: C07D239/42 , C07D403/04 , C07D405/04 , C07D409/14
摘要: Compounds of a certain formula 1 in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors. Formula (1), in which R1 is phenyl, phenyl substituted by R3 and/or R4, naphthalenyl, naphthalenyl substituted by and/or R6, aryl1, aryl1 substituted by R7 and/or R8, R9, R10 or R11, R2 is phenyl, phenyl substituted by R12 and/or R13, naphthalenyl, naphthalenyl substituted by R14 and/or R15, aryl2, aryl2 substituted by R16 and/or R17 or a radical selected from Formula (2).
摘要翻译: 其中R1和R2具有说明书所述含义的某种式1的化合物是新的激酶抑制剂。 式(1)其中R 1为苯基,被R 3和/或R 4取代的苯基,被R 1和/或R 6取代的萘基,萘基,芳基,被R 7和/或R 8,R 9,R 10或R 11取代的芳基, 被R 12和/或R 13取代的苯基,被R 14和/或R 15取代的萘基,萘基,芳基2,被R 16和/或R 17取代的芳基2或选自式(2)的基团。
-
5.Synergistic combination comprising roflumilast and (r,r) - formoterol 审中-公开
标题翻译: 协同组合包括罗氟司特和(r,r) - 福莫特罗公开(公告)号:US20060199865A1
公开(公告)日:2006-09-07
申请号:US10535817
申请日:2003-11-26
IPC分类号: A61K31/16
CPC分类号: A61K31/44 , A61K31/167 , A61K2300/00
摘要: The invention relates to the combined administration of roflumilast and R,R-formoterol for the treatment of respiratory tract disorders.
摘要翻译: 本发明涉及罗氟司特和R,R-福莫特罗联合给药以治疗呼吸道疾病。
-
6.Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases 审中-公开
标题翻译: 包含罗氟司特和抗胆碱能药物的协同组合,其选自异丙托铵,羟托吡酮和噻托铵盐,用于治疗呼吸系统疾病公开(公告)号:US20060147382A1
公开(公告)日:2006-07-06
申请号:US10550192
申请日:2004-03-26
IPC分类号: A61K31/4745 , A61K31/4415 , A61L9/04
CPC分类号: A61K45/06 , A61K31/439 , A61K2300/00
摘要: The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.
摘要翻译: 本发明涉及施用罗氟司特和选自异丙托铵,奥托溴铵或噻托铵盐的抗胆碱剂,用于治疗呼吸系统疾病。
-
公开(公告)号:US20060142308A1
公开(公告)日:2006-06-29
申请号:US10535816
申请日:2003-11-26
IPC分类号: A61K31/519 , A61K31/16
CPC分类号: A61K31/44 , A61K31/167 , A61K2300/00
摘要: The invention relates to the combined administration of roflumilast and formoterol for the treatment of respiratory tract disorders.
摘要翻译: 本发明涉及罗氟司特和福莫特罗联合用于治疗呼吸道疾病。
-
8.Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist 审中-公开
标题翻译: pde4或pde 3/4抑制剂和组胺受体拮抗剂的药物组合物公开(公告)号:US20050112069A1
公开(公告)日:2005-05-26
申请号:US10506875
申请日:2003-02-25
IPC分类号: A61K9/08 , A61K9/00 , A61K9/12 , A61K9/14 , A61K31/4375 , A61K31/4409 , A61K31/4425 , A61K31/4523 , A61K31/4545 , A61K45/06 , A61P11/00 , A61P11/06 , A61P11/08 , A61P37/08 , A61P43/00 , A61L9/04 , A61K31/4439 , A61K31/522 , A61K31/551
CPC分类号: A61K9/0073 , A61K31/4375 , A61K31/4425 , A61K31/4523 , A61K45/06 , A61K2300/00
摘要: The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.
摘要翻译: 本发明涉及用于治疗呼吸系统疾病的PDE4或PDE3 / 4抑制剂和组胺受体拮抗剂的组合施用。
-
公开(公告)号:US06613769B1
公开(公告)日:2003-09-02
申请号:US09601318
申请日:2001-01-22
申请人: Wolfram Bode , Luis Moroder , Pedro Jose Barbosa Pereira , Andreas Bergner , Robert Huber , Christian Sommerhoff , Norbert Schaschke , Thomas Bär , Thomas Martin , Josef Stadlwieser , Wolf-Rüdiger Ulrich , Andreas Dominik , Ulrich Thibaut , Daniela Bundschuh , Rolf Beume , Karl-Josef Goebel
发明人: Wolfram Bode , Luis Moroder , Pedro Jose Barbosa Pereira , Andreas Bergner , Robert Huber , Christian Sommerhoff , Norbert Schaschke , Thomas Bär , Thomas Martin , Josef Stadlwieser , Wolf-Rüdiger Ulrich , Andreas Dominik , Ulrich Thibaut , Daniela Bundschuh , Rolf Beume , Karl-Josef Goebel
IPC分类号: A61K31495
CPC分类号: C07D213/81 , C07C237/22 , C07C279/16 , C07D211/58 , C07D213/82 , C07D295/185 , C07D295/215 , C07D401/14
摘要: The invention relates to bifunctional tryptase inhibitors of formula (I) wherein H1 and H2 comprise a Q group and L is a linker of formula and the conformation of the H1, H2 and L groups is such that the groups are separated by a distance of from 20 to 45 Å. Pharmaceutical compositions and crystal forms of the compounds are described in addition to methods for producing and identifying such compounds, as well as the use of such compounds in methods of treating allergic and inflammatory diseases.
摘要翻译: 本发明涉及式(I)的双功能类胰蛋白酶抑制剂,其中H1和H2包含Q基团,L是式的连接体,并且H1,H2和L基团的构象使得基团被隔开距离为20 至45Å。 除了制备和鉴定这些化合物的方法之外,还描述了化合物的药物组合物和晶体形式,以及这些化合物在治疗过敏性和炎性疾病的方法中的用途。
-
-
-
-
-
-
-
-